Breaking News

CordenPharma Invests €9.7M in New CTD Facility at Plankstadt CoE

To design and install GMP Clinical Trial Development facility for the manufacture of oral solid dosage drug products.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CordenPharma, a full-service CDMO of Active APIs, excipients, drug products and packaging services, is investing €9.7 million to design and install a new GMP Clinical Trial Development (CTD) facility for the manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.   CordenPharma Plankstadt is the company’s Centre of Excellence for the Development and Manufacture of Highly Potent Oral Solid Drug Products for compounds that have an OEL level < 1 µg/m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters